EVLO (Evelo Biosciences) EBIT: $-75.97 Mil (TTM As of Sep. 2023)

What is Evelo Biosciences EBIT?

Evelo Biosciences EVLO -99.00% EBIT is $-75.97 Mil as of Sep. 2023.

Evelo Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-11.22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-75.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Evelo Biosciences's annualized ROC % for the quarter that ended in Sep. 2023 was -87.42%. Evelo Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -994.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Evelo Biosciences (OTCPK:EVLO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Evelo Biosciences's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-41.56 * ( 1 - 0.14% )	/	( (57.882	+	37.069)	/ 2 )
=	-41.501816	/	47.4755
=	-87.42 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	20.819	-	7.215	-	( 7.622	-	max(0, 55.541	-	11.263	+	7.622	))
=	57.882

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	20.627	-	4.383	-	( 17.262	-	max(0, 39.761	-	18.936	+	17.262	))
=	37.069

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Evelo Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-44.876	/	( ( (8.134 + max(-5.295, 0))	+	(0.894 + max(-4.139, 0)) )	/	2 )
=	-44.876	/	( ( 8.134	+	0.894 )	/	2 )
=	-44.876	/	4.514
=	-994.15 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.641)	-	(7.215	+	0	+	1.721)
=	-5.295

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.674)	-	(4.383	+	0	+	1.43)
=	-4.139

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Evelo Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-75.965	/	0.000
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences EBIT Related Terms

Evelo Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's EBIT can be seen below:

Evelo Biosciences EBIT Chart

Evelo Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-58.10

-86.36

-91.15

-118.14

-108.93

Evelo Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-29.67	-21.16	-24.09	-19.50	-11.22

EVLO vs IMNN, EDSA, TMBR: EBIT Comparison

For the Biotechnology subindustry, Evelo Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's EV-to-EBIT falls into.

Save Embed

Evelo Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.97 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-75.97 Mil mean?

Evelo Biosciences (EVLO) has a EBIT of $-75.97 Mil as of Sep. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Evelo Biosciences.

Is Evelo Biosciences' EBIT too high?

Evelo Biosciences' current EBIT is $-75.97 Mil.

How does Evelo Biosciences' EBIT compare to IMNN and EDSA?

Evelo Biosciences' EBIT of $-75.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Evelo Biosciences. Evelo Biosciences's current EBIT is $-75.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evelo Biosciences stock overvalued right now?

Evelo Biosciences (EVLO) has a current EBIT of $-75.97 Mil. The current EBIT is $-75.97 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current EBIT is $-75.97 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies IMNN EDSA TMBR EIGR SIGY GRTX CMRA ONVO VYNE ARAV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 620 Memorial Drive, Cambridge, MA, USA, 02139

Website https://www.evelobio.com

Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.